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ABSTRACT 
Objective: Formulation and characterization of clobetasol propionate (CP) and pramoxine hydrochloride (PH) loaded nanostructured lipid carriers 
(NLC) offering improved performance in terms of drug loading and long-term stability for topical drug delivery.  
Methods: Drug-loaded NLC formulation was designed by melt-emulsification ultrasonication technique, by fluctuating the concentration of stearic 
acid and oleic acid. Poloxamer F68 and tween 80 were used as surfactants in the formulation and soya lecithin was used as stabilizer and co-
surfactant. Differential scanning calorimetry (DLS), scanning electron microscopic studies (SEM), transmission electron microscopy (TEM), fourier 
transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), x-ray diffraction (XRD), are the techniques used to characterize 
the preparations. Optimized drug-loaded formulations were evaluated for particle size, zeta potential, entrapment efficiency, in vitro drug release, 
hemocompatibility assay and cytotoxicity screening. 
Results: For drug loaded formulation the particle size was found in nanometric range. In vitro drug release was carried out using dialysis 
membrane and drug release after 24h was found to be 90.98 %±1.89 for CP and 79.81 %±4.20 for PH. 
Conclusion: The formulated NLC is a potential approach for sustained release of drug which may reduce systemic side effects, increase skin 
retention time and duration of action. Further in vivo studies will confirm the effect of NLC to increase skin retention time, decreases systemic 
absorption of the corticosteroid thereby avoiding side effects. 
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INTRODUCTION 
Atopic dermatitis (AD) is a highly pruritic chronic inflammatory skin 
disease that commonly presents during early childhood [1] and is 
often thought as synonymous with eczema. In several cases, atopic 
dermatitis is the first manifestation of atopy and is frequently 
associated with personal and family history of respiratory allergy 
and have profound effects on patient’s lives, career, choices and 
social interactions [2]. The prevalence of AD has increased 
exponentially over the past few decades in industrialized nations 
affecting 15% to 30% and 2% to 10% of children and adults, 
respectively [3]. Among individuals infected with AD, up to 60% of 
males and 55% of females are diagnosed under the age of 1 and less 
than 2% of new cases occur after the age of 20 [4]. 
Nanostructured lipid carriers (NLC) are the second generation SLN 
composed of solid lipid matrix which are incorporated with liquid 
lipids [5]. The small size of the lipid particles ensures close contact 
to stratum corneum (SC) and can increase the amount of drug 
penetrating into mucosa or skin. Due to their solid lipid matrix, a 
controlled release from these carriers is possible. This becomes an 
important tool when it is necessary to supply the drug over a 
prolonged period of time, to reduce systemic absorption, and when 
drug produces irritation in high concentrations [6]. NLCs have a 
higher loading capacity for a number of active compounds, and the 
potential expulsion of active compounds during storage is 
minimized [7]. Because of the small size of NLCs, close contact with 
the SC is guaranteed and the amount of the drug penetrated into the 
skin can be increased [8]. 
Corticosteroids have been successfully employed for the treatment 
of several inflammatory skin conditions. Their clinical efficacy is 
associated with drug skin retention; however, they can permeate the 
SC, reaching deeper skin layers, which may cause local and systemic 
side effects. CP is a super-potent topical corticosteroid. Skin atrophy, 
skin infections and hypothalamic-pituitary-adrenal (HPA) axis 
suppression are some of the possible side effects of topical 
corticosteroids. Improvements in the safety of topical corticosteroid 
therapy may be achieved by drug nanoencapsulation, which can 
increase the drug’s accumulation in the skin while minimizing deep 
drug permeation and adverse systemic effects [9]. In the present 
work, CP and PH were encapsulated in NLCs to increase drug 
retention in the outer skin layers and avoid systemic absorption. PH 
is a local anaesthetic that will help to reduce the itching sensation, 
currently, there are no combinational dosage form of these two 
drugs available in the market. 
MATERIALS AND METHODS 
Materials 
CP was gifted by mahima life sciences, haryana, India. PH was 
purchased from sigma-aldrich Co. LLC. Stearic acid was obtained 
from nice chemicals; kochi. Oleic acid is obtained from loba chem. 
Pvt. Ltd, mumbai. Poloxamer F68 was shipped from research-lab 
fine chem industries mumbai, India and Tween 80 was procured 
from nice chemicals, kochi. Soya lecithin is obtained from hi media 
laboratories Pvt. Ltd. mumbai, India. Millipore water was used 
during the course of the study. 
Preformulation studies 
The melting point of CP and PH (both are API) were determined by 
open capillary tube method. Methanol, dimethyl sulphoxide (DMSO), 
diethyl ether and ethanol are the organic solvents used to determine 
the solubility of pure drugs by the shake flask method reported as 
[10]. Solution of both drugs ranging from 2-10 µg/ml were scanned 
from 200-400 nm using a UV-visible spectrophotometer, support to 
define the absorption maxima (λ max). Partition coefficient was done 
by equal millilitre of N-octanol and water in separating funnel. 100 
mg of the drug was added to it, which is then equilibrated for 2h at a 
constant temperature with intermittent shaking at regular intervals 
and separate the aqueous layer and organic layer. Collect 1 ml of the 
aqueous layer and the concentration of drug in it were determined 
at 240 nm by UV spectrophotometer. The same procedure was 
repeated for PH and the concentration of drug in it was determined 
at 224 nm by UV Spectrophotometer [10]. 
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Preparation of clobetasol and pramoxine loaded NLC 
Nine different batches of formulations were prepared by melt-
emulsification ultra-sonication method (fig. 1) by varying the 
concentration of lipids and surfactants (table 1). In brief, the 
required amount of solid lipid and liquid lipid was occupied in lipid 
phase and amount of surfactants, co-surfactants and stabilizer were 
taken in the aqueous phase. Accurately weighed the amount of drug 
is added to lipid phase and both phases were heated separately at 80 
°C for 20 min. Then the aqueous phase was added drop by drop to 
the lipid phase upon magnetic stirring at 750 rpm, maintaining a 
temperature above 80 °C. This primary emulsion is then probe 
sonicated for 15 min under 70% amplitude and 6-2 pulse 
immediately cooled in ice water bath for the formation of NLC [11]. 
 
Table 1: Composition of ingredients used for formulating the nano lipid carrier 
Trials Stearic acid(mg) Oleic acid(ml) Poloxamer F 68(mg) Tween 80(ml) Soya lecithin(mg) Distilled water (ml) 
1 280 120 150 - - 20 
2 700 300 150 1.5 - 20 
3 500 300 - 1 - 20 
4 350 1 80 0.5 - 20 
5 1000 2 160 1 - 40 
6 1600 3 380 0.4 375 50 
7 1750 3 375 0.4 375 50 
8 1750 3 500 0.5 375 50 
9 1750 3 500 0.5 425 50 
 
 
Fig. 1: Preparation of NLC by melt-emulsification ultra-sonication method 
 
Characterization of optimized drug loaded NLC 
Dynamic light scattering (DLS) 
For determining the particle size and zeta potential, DLS method 
with a computerized system of nano zeta sizer was employed [12].  
Scanning electron microscopy (SEM)  
SEM was utilized to analyze the morphological characteristics of the 
drug carrier system and the formulations using scanning electron 
microscope (VEGA3 TESCAN) at an accelerated voltage of 20Kv at 
x1000 and x10000 magnifications [12]. 
Transmission electron microscopy (TEM) 
Morphological characters were analysed with transmission electron 
microscopy technique by using negative staining method. About 5 µl 
of the stained sample was placed on the grid crusted with copper 
followed by removing the spare amount of stains, air dried in room 
temperature and images were taken [13]. 
Fourier transform infrared spectroscopy (FTIR) 
FTIR, a qualitative analyzer used to characterize the properties of 
each agent in the formulation. It was conducted by using a perkin 
elmer FTIR (USA) instrument and ranging from 4000-500 cm-1 the 
dried sample which was placed in sample holder were scanned [13].  
Differential scanning colorimetry (DSC) 
The DSC thermogram of various samples were carried out by 
weighing the sample about 5 mg, sealed in an aluminum pan of 40 µl 
capacity and equilibrated at 25 °C were subjected to DSC run over a 
temperature range 10-325 °C for heating rate of 10 °C/minute in an 
inert nitrogen gas atmosphere [14]. 
X-ray diffraction study (XRD) 
The X–ray diffraction patterns were recorded, under CuKα 
monochromatised radiation, voltage 40 KV and current of 20 mA at 
ambient temperature. The data of pure drugs and drug-loaded nano 
lipid carriers were collected in the continuous scan mode from 2°–4° 
(2θ) at an angular increment of 0.02°/sec and count time of 1 
sec/step [15]. 
Entrapment efficiency (EE) 
Entrapment efficiency gives an idea about the percentage of the drug 
that is successfully entrapped/adsorbed into nanoparticles. For 
ultracentrifugation method [16], 500 µl of drug contained sample 
was filled in the ultra-centrifugal filter unit’s Hermle labortechnik 
GmbH (Germany). It was running at 10,000 rpm for 30 min in a 
centrifuge, the liquid in the topmost layer was diluted with methanol 
and scanned in shimadzu uv-spectrophotometer for the 
quantification of the drug. 
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In vitro release study 
Dialysis membrane technique is used for in vitro drug release study. 
The prepared NLC (2-5 ml) is introduced dialysis membrane (pore 
size 0.2 µm) which is hermetically sealed in one end of the open-end 
tube. This tube was then immersed in the 30 ml solution of 
phosphate buffer solution(PBS) 5.5 and placed in the orbital shaking 
incubator set at temperature 37 °C (to simulate the human skin 
condition) and at 50 rpm. At predetermined intervals of 1, 2, 4, 6, 8, 
10, 12 and 24 h, aliquots of 1 ml were withdrawn and replaced with 
an equal volume of fresh buffer solution. These samples were made 
up to 10 ml using PBS 5.5 and the absorbance was measured using 
UV spectrophotometer at 240 and 224 nm. The amount of drug 
released was calculated and the percentage drug released was 
plotted against time [17].  
Kinetic modeling of drug release  
The data obtained from the drug release studies of the NLC 
formulations were fitted to various models such as Zero order, First 
order, Higuchi model, Korsmeyer–peppas model and Hixson-crowell 
cube root law to ascertain the kinetic modelling of drug release [18]. 
The plots were drawn using the computational system and the 
regression equations were obtained for each plot. The correlation 
coefficient values (r2) of the plots were obtained. The model with the 
highest correlation coefficient (r2 value approaching unity) was 
chosen as the best fit model. 
In vitro haemocompatibility study 
5 ml of blood was immediately collected in an EDTA coated 
vacutainer (to prevent clotting), then centrifuged at 15000 rpm for 
15 min to separate RBC and plasma. After that RBC were diluted 
with normal saline in ratio 1:9 for further studies. The different 
concentration of drug loaded NLC ranging from 20-80µg/ml were 
added to 500 µl diluted blood and made up to 1 ml with normal 
saline, incubated for 24h. 0.1% Triton treated blood sample was 
used as positive control and normal saline as negative control. After 
incubation, centrifuged at 3500 rpm for 10 min at 4 °C. From the 
above solution, 100 µl supernatant was collected and absorbance 
measured at 540 nm [19]. 
MTT assay 
MTT [3-(4, 5-dimethylimidazole-2-yl)-2, 5-diphenyl tetrazolium] 
assay was used to access the cytocompatibility and cytotoxicity of 
the prepared NLC formulation. L929 (fibroblast) cell line was 
purchased from the national centre for cell sciences (NCCS) pune 
was maintained in dulbecco’s modified eagle’s media (DMEM) 
(Himedia). The cell line was cultured in 25 cm2 tissue culture flask 
with DMEM supplemented with 10% fetal bovine serum, L-
glutamine, sodium bicarbonate and an antibiotic solution 
containing: Penicillin (100U/ml), streptomycin (100µg/ml), and 
amphotericin B (2.5µg/ml). Cultured cell lines were kept at 37 °C in 
a humidified 5% CO2 incubator (NBS Eppendorf, Germany). The 
viability of cells was evaluated by direct observation of cells by 
inverted phase contrast microscope and followed by MTT assay 
method [20]. 
In vitro skin permeation studies 
Porcine ear skin obtained from a local abattoir was used to conduct 
in vitro skin permeation procedure. Raw skin was cleaned in cold 
running water followed by removing the hair and fats by using 
scalpel blade. The portion corresponding to the penetration region 
was stamped out, frozen at-20 °C and kept for a period up to 3 m. 
The experiment was conducted by Franz-diffusion cell [21], the skin 
sample were sandwiched between receptor slot containing 7 ml of 
phosphate buffer (pH 5.5) and an optimized formulation containing 
donor compartment. It was uniformly stirred at 100 rpm maintained 
at 33±2 °C. Withdraw the sample from the receptor compartment at 
predetermined intervals and replaced the same amount with buffer 
and triplicate the experiment. 
Stability studies 
The optimized NLC formulation was stored at room temperature (at 
25 °c), refrigerator temperature (4-8 °c) and accelerated condition 
(40±2 °C, 75±5% RH) for a period of 3 m. The colour, appearance 
and odor were examined in every 30 d for determining physical 
stability. Then the formulation was estimated using for particle size 
(PS) and zeta potential [22]. 
RESULTS AND DISCUSSION 
Preformulation studies 
Preformulation studies were done for confirming the identity, purity 
and to establish a suitable drug profile. The melting point of the CP 
(A) and PH (B) was found to be 195 °C and 182 °C respectively, 
equivalent with the monograph value. The solubility of the drugs 
was determined in different solvents such as methanol, DMSO, 
diethyl ether, ethanol (table 2). From the result, it is clearly evident 
that both drugs are freely soluble (96.662 mg/ml and 93 mg/ml) in 
DMSO. CP showed less solubility in water whereas PH showed more 
solubility as compared with CP.  
The λmax of the drug A and B was determined in methanol and 
phosphate buffer having pH 5.5 was found to be 240 nm and 224 nm 
respectively was in accordance with official standards. Log P value of 
both drugs was found to be nearly 3, any compounds with a log p-
value greater than 2 indicate the lipophilicity of chemical agents. 
  
Table 2: Solubility profile of CP (A) and PH (B) 
Solvent Amount of drug (A) dissolved (mg/ml) Amount of drug (B) dissolved (mg/ml) 
Water 0.70 66  
Ethanol 11.31 66  
Methanol 20.64 66  
DMSO 96.62 93 
Dichloromethane 3.26 66 mg/ml 
pH buffer 5.5 2.64 53 mg/ml 
 
Characterization of optimized formulation 
Particle size, particle size distribution, and zeta potential 
The plain NLC formulation shows lowest particle size 
(68.49±17.59 nm) and the drug-loaded NLC formulation shows a 
particle size of 86.76±7.48 nm, a single narrow peak can be seen in 
the fig. 2A and 2C. The value of polydispersity index (PDI) value 
was found to be 0.473 which is below 1.0, suggesting that the 
optimized NLC formulation having particle size in nano range 
which remains stable and will not convert macro range particles 
and suggesting that the NLC was monodispersed PDI is a measure 
of particle homogeneity and it varies from 0.0 to 1.0. When the 
value of polydispersity index is closer to zero, more homogenous 
the particles are. Many papers have shown that zeta potential (fig: 
2B and 2D) influences the stability of NLC, the high value of zeta 
potential indicates electrostatic repulsion between two particles of 
the optimized formulation [23].  
DLVO theory states that electric double layer repulsion will 
stabilize NLC and aggregation is not expected to take place, due to 
the highly negative charge of particles. In this study, by increasing 
the concentration of lipids helps to achieve the desired particle 
size ie, <100 nm with single narrow peak and stable zeta value. 
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Fig. 2(A) and (C): Particle size of optimized plain and drug-loaded NLC (B) and (D) zeta potential of optimized plain and drug-loaded NLC 
 
Scanning electron microscopic studies 
SEM analysis was also performed to obtain more information 
about the particle size and shape. The SEM microphotographs of 
pure drugs CP, PH and drugs loaded NLC are shown in fig. 3A, 3B 
and 3C respectively. Fig. 3A and 3B disclose the irregular 
crystalline nature of pure drugs, fig. 3C shows spherical 
morphology and the size of the NLCs was found within the 
nanometer range. SEM also revealed the agglomeration of 
nanoparticles which might be due to the lipid nature of the carrier 
and the drying process during sample preparation prior to SEM 
analysis. 
 
 
Fig. 3A: SEM image of CP 
 
Fig. 3B: SEM image of PH
 
 
Fig. 3C: SEM image of drug loaded NLC 
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Transmission electron microscopy (TEM) 
The surface morphology and mean diameter of optimized NLC 
formulation was visualized using TEM. The observed diameters of 
particles were found to be consistent with the particle size obtained 
in DLS i.e. 96.97 nm (fig. 4). Developed lipid nanoparticles possessed 
spherical and smooth surface. By using the TEM result the particle 
size was confirmed. 
Fourier transform infrared (FTIR) spectroscopy 
The peaks were found in accordance with the monograph (I. P). The 
principle absorption peaks of CP were at 3304 cm-1 (aromatic C-H), 
2954 cm-1 (aliphatic C-H), 1675 cm-1 (aldehyde C=O stretch), 1570 
cm-1 (C=C stretch). PH was at 2937 cm-1 (aliphatic C-H stretch) 3258 
cm-1 (aromatic C-H stretch). The FTIR Spectrum of clobetasol-
pramoxine-loaded NLC is shown in fig. 5, the IR spectra showed 
characteristic peaks at 3462.89 cm-1 (aromatic C-H stretching), 
above 3000 cm-1 broad peak (O-H stretch), 2855.23 cm-1, 2923.42 
cm-1 (aliphatic C-H–stretching), 1639.42 cm-1 (C=O–stretching), 
1099.12 cm-1(C-O stretch),582.92 cm-1 (C-F-stretching). All the 
characteristic peaks for both the drugs were found to be present in 
the NLC indicating compatibility of the drug with excipients. 
 
 
Fig. 4: TEM image of drug loaded NLC 
 
 
Fig. 5: FTIR Spectrum of clobetasol-pramoxine-loaded NLC 
 
 
Fig. 6: DSC thermogram of (A) CP (B) PH (C) plain NLC (D) drug loaded NLC
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Differential scanning calorimetry (DSC) analysis 
The results of the DSC analysis of CP, PH, plain NLC and the drug-
loaded NLC formulation are shown in fig. 6. The DSC thermogram of 
CP showed an exothermic peak at 196 °C, which is the reported 
melting point of the CP (fig. 6A) and the DSC thermogram of PH 
showed an exothermic peak at 171-181 °C, which is the reported 
melting point of the PH (fig. 6B). Drug-loaded NLC showed a large 
endothermic peak at 91.19 °C. It is observed from the DSC 
thermogram that the exothermic peak of pure drugs at about 196 °C 
and 181 °C no longer exists in the DSC traces of the drug-loaded 
NLCs. Taking into consideration the drug–crystal–free particle 
surface, it is apparent that CP and PH is amorphously dispersed 
within the nanoparticles, which is preferable for a sustained release 
system. Furthermore, the inclusion of drug molecules in the lipid is 
normally accompanied by a depression in the lipid’s melting point. 
X-ray diffraction study 
X-ray diffractograms of CP, PH, plain NLC and the drug-loaded NLC 
are presented in fig. 7. The XRD patterns of CP and PH showed 
numerous diffraction peaks at diffraction angles (2θ) 26.69 °, 20.55 
°,14.61 °, 12.84 °, 10.27 °, 34.07 °, 47.16 °, 15.32 °, 12.20 °,25.43 °, 
28.09 °, 31.51 °, 6.12 ° and 9.10 ° corresponding to its crystalline 
pattern. Such characteristic patterns were absent in the diffraction 
peaks of plain NLC and drug-loaded NLC, indicating the presence of 
the drug in the amorphous form, confirming the DSC data. 
 
 
Fig. 7: PXRD diffractogram of (A) CP, (B) PH, (C) Plain NLC, (D) Drug- loaded NLC 
 
Entrapment efficiency 
The average entrapment efficiency of the optimized formulation was 
found to be: CP 78%±3.26 and PH 89.76%±2.66. It might be due to 
the incorporation of liquid lipids into solid lipids which have led to 
massive crystal order disturbance [24]. Greater imperfections in the 
crystal lattice leave enough space to accommodate drug molecules, 
which ultimately improved drug-loading capacity and drug 
entrapment efficiency. The percentage entrapment efficiency is 
mainly depending on the nature of the drug and lipids. As CP and PH 
are lipophilic drugs with Log P of 3.5 to 3.3 respectively their 
entrapment efficiency is high. 
In vitro drug release studies 
In vitro drug release study was performed for NLC formulation 
revealing a biphasic release pattern of drugs i.e. a burst release in 
the initial stage followed by a sustained release. About 15-20 % of 
loaded drugs were released within first 2 h, followed by the release 
of 90.98-79.81% within 24 h of the assay. The initial burst release 
might be due to the presence of the unentrapped drug in the NLC 
dispersion, another reason might be due to most of the liquid lipid 
being located in the outer shell of the nanoparticles, which lead to a 
drug-enriched shell that is related to burst release at the initial stage 
[25]. The oleic acid enriched outer layers possessed a soft and 
considerably higher solubility for lipophilic drugs, which ultimately 
increased the loading of the drug and could be easily released by 
diffusion or matrix erosion. The release time profile data of CP and 
PH from drug loaded NLC are represented in the fig. 8. 
Kinetic modelling of in vitro drug release 
The release kinetics was determined by fitting the data obtained 
from in vitro release studies of NLC into standard release equation, 
i.e. zero order, first order, higuchi and korsmeyer-peppas and 
represented in table 4. The model that fits best release data was 
selected based on correlation coefficient value of various models. 
The results suggested that release of drug from NLC follows first 
order release model and as indicated by the higher R2 value of 
0.9807 and 0.9788 for CP and PH respectively. This type of kinetics 
indicates that the drug release is dependent of drug concentration. 
When the release data were analysed using the korsmeyer peppas 
equation, the value of release exponent ‘n’ was found to be 0.7232 
for CP and 0.8587 for PH, which indicates that the mechanism of 
drug release from NLC follows non-fickian diffusion. 
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Fig. 8: In vitro drug release of CPand PH from optimized NLC. The values are expressed as mean±SD; n=3 
 
Table 4: Kinetic modelling of A and B release from NLC 
Optimized formulation R2value 
Zero order model First order model Higuchi model Peppas model n 
A 
B 
0.8871 
0.8101 
0.9807 
0.9788 
0.9801 
0.9788 
0.9809 
0.9433 
0.7202 
0.8587 
 
In vitro haemolysis assay 
Haemocompatibility test was carried out to check the compatibility of 
the drug and formulation with blood, since it may come in contact with 
the blood even on topical administration. The degree of haemolysis is a 
sensitive indicator of the extent of damage to RBC. In the present study, 
different concentrations of optimized formulations were tested and 
showed no evidence of haemolysis (<0.5%) after incubation for the 
specified time period. The obtained results were compared with 
standard normal saline and the positive control triton X. As per the 
results obtained the haemolytic ratios of the NLCs were below 5% which 
is the safe haemolytic ratio for biomaterials in accordance with ISO/TR 
7406. It confirms that the NLCs are free from the risk of haemolysis. 
MTT assay: L929 Normal cell line 
In vitro cytotoxicity screening was carried by MTT assay on L929 
normal fibroblastic cell line. Here absorbance rate or percentage cell 
viability of the experimental samples were less than the control 
group which indicates reduced cell proliferated rate or decreased 
overall cell viability rate. Prepared NLC formulation was tested for 
cytotoxicity in different concentrations like 100µg/ml, 50µg/ml, 
25µg/ml, 12.5µg/ml, 6.25µg/ml. Percentage viability was found to 
be 96.95 to 64.20 (minimum to maximum dose) which indicates that 
prepared NLC formulation is not toxic towards the normal cell line. 
The percentage viability of prepared NLC on L929 cell lines are 
shown in fig. 9. 
 
 
Fig. 9: Percentage viability of L929 normal cell line on treating with prepared NLC (A) control (B) 6.25µg/ml (C) 12.5 µg/ml (D) 25 µg/ml 
(E) 50 µg/ml (F) 100 µg/ml. The values are expressed as mean±SD; n=3, p<0.05 
 
In vitro skin permeation studies 
The in vitro permeation study for CP-PH NLC was carried out. The results 
are shown in table 5 and found out that 75.85 μg/cm2CP and 65.588 
μg/cm2of PH permeated through 2.54 cm2 area of skin. The major 
parameter influencing the drug permeability through the skin is the 
particle size which is in nanometric range ie; <100 nm can easily penetrate 
via SC [26]. Moreover, lipids are skin friendly and compatible to the 
epidermis region so that interaction between keratinocytes enriched 
topical area and NLC would be higher through vanderwaal force.  
Oleic acid act as liquid lipid as well as permeation enhancer able to 
disrupt the lipids and corneocytes cause an increase in diffusion 
coefficient. 
 
Table 5: Amount of drugs permeated per cm2 of skin vs. time 
Time in h Amount of drug permeated in µg/cm² 
CP PH 
0 0 0 
2 4.392±0.035 3.913±0.063 
4 10.984±0.092 8.9670±0.033 
6 19.378±0.061 14.715±0.052 
8 30.666±0.955 23.622±0.096 
10 42.913±0.861 33.802±0.939 
12 58.715±1.221 48.612±1.766 
24 75.856±1.109 65.588±1.491 
The values are expressed as mean±SD; n=3 
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Stability studies 
The stability studies of the optimized formulation were carried out 
at room temperature (30±2 °C), at refrigerator temperature (4±2 °C) 
and at accelerated condition (40±2 °C, 75±5% RH) for 3 mo. Fig. 10A 
and 10B portrayed the particle size and zeta potential of the CP-PH 
loaded NLC in three dissimilar storage conditions. The size 
distribution varies from 86±0.09 nm to 114±0.29 nm after one 
month and further increased to154±1.56 nm. In fact, it showed a 
relevant increase in particle size (p<0.05) at an accelerated 
temperature as compared with refrigerated temperature in the 
matching period. Upon storage, at room temperature and 
accelerated temperature, the formulation shows an increase in the 
particle size and decrease in zeta potential. In-room temperature 
and accelerated condition, there was a significantly visible particle 
aggregation resulted in increasing particle size.  
Zeta value decreased from-39±0.04 to-19±0.83 and-39±0.03 to-
12±1.20 in accelerated and room condition respectively indicates 
less stability. But here observed no drastic changes that will affect 
the particle size and zeta potential at 4±2 °C, so the stability of NLC 
stored at refrigerated temperature. 
  
 
Fig. 10: A. Particle size of optimized NLC after storage at different temperatures. Each value represents mean±SD (n=3) 
 
 
Fig. 10: B. Zeta potential of optimized NLC after storage at different temperatures. Each value represents mean±SD (n=3) 
 
CONCLUSION 
Drug-loaded NLC was prepared by melt emulsification ultra-
sonication method, prior to which preformulation studies of both 
the drugs were carried out. NLC was optimized by altering the 
composition of various ingredients of the formulation until the NLC 
were obtained of the desired size range. Drug-loaded NLC were 
characterized by particle size analysis, zeta potential measurement, 
FT-IR, SEM, XRD, DSC and TEM. DSC and XRD studies have indicated 
the presence of CP and PH in the amorphous or molecularly 
dispersed state within the NLC and the NLCs were found to be 
spherical in shape having a narrow size distribution and were stable. 
The optimized drug loaded formulation was assessed for in vitro 
drug release, ex vivo skin permeation studies, in vitro haemolysis and 
MTT assay. In vitro studies showed a sustained release behaviour of 
both the drugs following non fickian release pattern and the ex vivo 
skin permeation studies have showed good permeation of both the 
drugs. In vitro haemolysis assay was done to evaluate the 
haemocompatibility of the formulation, which showed that the 
formulations are haemocompatible with haemolytic percentage<5%. 
MTT assay results showed that the prepared NLC is not toxic 
towards the normal cell line.  
The stability studies conducted revealed the ideal storage conditions 
for the NLC are refrigeration condition. 
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